NCCN Grants Category 1 Recommendation to Pexidartinib for TGCT

Sep 26, 2019 – The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma to include a category 1 recommendation for pexidartinib for the treatment of patients with tenosynovial giant cell tumor (TGCT). The recommendation is based on findings from the placebo-controlled phase III ENLIVEN trial, which was also the basis for pexidartinib’s August 2019 FDA approval for the treatment of … (leggi tutto)